Skip to main content

Compare Stocks

Date Range: 

 Zai LabBioMarin PharmaceuticalElanco Animal HealthOno PharmaceuticalAlnylam Pharmaceuticals
SymbolNASDAQ:ZLABNASDAQ:BMRNNYSE:ELANOTCMKTS:OPHLFNASDAQ:ALNY
Price Information
Current Price$151.68$75.51$33.95$23.80$132.92
52 Week RangeBuyBuyBuyN/ABuy
MarketRank™
Overall Score1.62.11.91.11.8
Analysis Score3.54.32.30.03.3
Community Score2.43.12.22.23.3
Dividend Score0.00.00.00.00.0
Ownership Score1.71.73.30.01.7
Earnings & Valuation Score0.61.31.93.10.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ABuy
Consensus Price Target$197.85$118.20$32.23N/A$168.73
% Upside from Price Target30.44% upside56.54% upside-5.07% downsideN/A26.94% upside
Trade Information
Market Cap$14.36 billion$13.80 billion$16.06 billion$12.24 billion$15.62 billion
Beta0.950.710.861.061.47
Average Volume494,2581,194,6273,907,9912,767641,944
Sales & Book Value
Annual Revenue$12.98 million$1.70 billion$3.07 billion$2.69 billion$219.75 million
Price / Sales1,106.468.105.234.5571.10
CashflowN/A$0.58 per share$2.06 per share$1.09 per shareN/A
Price / CashN/A130.2216.4821.92N/A
Book Value$5.07 per share$17.38 per share$14.87 per share$10.16 per share$12.90 per share
Price / Book29.924.342.282.3410.30
Profitability
Net Income$-195,070,000.00$-23,850,000.00$67.90 million$549.28 million$-886,120,000.00
EPS($3.03)$0.07$1.06$1.09($8.11)
Trailing P/E RatioN/A17.28N/A21.64N/A
Forward P/E RatioN/A142.4737.7214.60N/A
P/E GrowthN/A3.894.13N/AN/A
Net MarginsN/A45.74%-8.45%22.14%-222.19%
Return on Equity (ROE)N/A4.34%3.43%11.29%-65.96%
Return on Assets (ROA)N/A2.84%2.04%9.71%-31.38%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.26%0.67%N/AN/A
Current Ratio8.57%3.20%1.75%2.78%5.32%
Quick Ratio8.46%2.38%0.90%2.33%5.18%
Ownership Information
Institutional Ownership Percentage81.32%97.65%86.83%N/A92.35%
Insider Ownership PercentageN/A2.15%0.12%N/A3.50%
Miscellaneous
Employees1,1943,05910,2003,5601,453
Shares Outstanding94.69 million182.74 million473.00 million514.12 million117.55 million
Next Earnings Date8/10/2021 (Estimated)8/3/2021 (Estimated)7/29/2021 (Estimated)N/A8/5/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
$201.22 Million in Sales Expected for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) This Quarter$201.22 Million in Sales Expected for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) This Quarter
marketbeat.com - May 14 at 4:41 AM
Heres Why Alnylam Pharmaceuticals, Inc.s (NASDAQ:ALNY) CEO Might See A Pay Rise SoonHere's Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Might See A Pay Rise Soon
nasdaq.com - May 12 at 9:48 AM
Alnylam Announces New Advances in ATTR Amyloidosis ProgramAlnylam Announces New Advances in ATTR Amyloidosis Program
finance.yahoo.com - May 11 at 7:26 AM
Regeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Call TranscriptRegeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Call Transcript
msn.com - May 6 at 4:30 PM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases FY 2021 Earnings GuidanceAlnylam Pharmaceuticals (NASDAQ:ALNY) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 6 at 2:50 PM
Evercore ISI Stick to Their Buy Rating for Alnylam PharmaceuticalsEvercore ISI Stick to Their Buy Rating for Alnylam Pharmaceuticals
investing.com - May 3 at 10:06 AM
Leerink Partners Keeps Their Hold Rating on Alnylam Pharma (ALNY)Leerink Partners Keeps Their Hold Rating on Alnylam Pharma (ALNY)
smarteranalyst.com - May 3 at 10:06 AM
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO ® (lumasiran)Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO ® (lumasiran)
businesswire.com - May 3 at 10:06 AM
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
finance.yahoo.com - May 3 at 10:06 AM
Berenberg Bank Stick to Their Hold Rating for Alnylam PharmaceuticalsBerenberg Bank Stick to Their Hold Rating for Alnylam Pharmaceuticals
investing.com - April 30 at 10:36 PM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues  Earnings ResultsAlnylam Pharmaceuticals (NASDAQ:ALNY) Issues Earnings Results
americanbankingnews.com - April 30 at 6:12 PM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY) and Cryolife (CRY)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY) and Cryolife (CRY)
smarteranalyst.com - April 30 at 12:35 PM
Alnylams (ALNY) Q1 Loss Narrower Than Expected, Revenues BeatAlnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - April 30 at 12:35 PM
Morgan Stanley Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $205.00Morgan Stanley Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $205.00
americanbankingnews.com - April 30 at 10:12 AM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $205.00 at Morgan StanleyAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $205.00 at Morgan Stanley
marketbeat.com - April 30 at 8:18 AM
Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period ActivityAlnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity
wallstreet-online.de - April 29 at 9:33 PM
Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call TranscriptAlnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transcript
fool.com - April 29 at 5:14 PM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Updates FY 2021 Earnings GuidanceAlnylam Pharmaceuticals (NASDAQ:ALNY) Updates FY 2021 Earnings Guidance
americanbankingnews.com - April 29 at 12:18 PM
Alnylam: Q1 Earnings SnapshotAlnylam: Q1 Earnings Snapshot
apnews.com - April 29 at 11:32 AM
Heres what Wall Street expects from Alnylam Pharmaceuticalss earningsHere's what Wall Street expects from Alnylam Pharmaceuticals's earnings
markets.businessinsider.com - April 27 at 8:28 PM
Immuneering Expands Board of Directors with Addition of Senior Biotechnology Executive Laurie KeatingImmuneering Expands Board of Directors with Addition of Senior Biotechnology Executive Laurie Keating
ca.finance.yahoo.com - April 27 at 3:27 PM
Alnylam Pharmaceuticals (ALNY) Shares Cross Above 200 DMAAlnylam Pharmaceuticals (ALNY) Shares Cross Above 200 DMA
nasdaq.com - April 26 at 6:10 PM
Alnylam FDA submission aims to expand biotech’s franchise of gene-silencing drugsAlnylam FDA submission aims to expand biotech’s franchise of gene-silencing drugs
medcitynews.com - April 25 at 7:19 PM
 Analysts Anticipate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Post Earnings of -$1.75 Per Share Analysts Anticipate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Post Earnings of -$1.75 Per Share
americanbankingnews.com - April 24 at 8:14 AM
Leerink Partners Stick to Their Hold Rating for Alnylam PharmaceuticalsLeerink Partners Stick to Their Hold Rating for Alnylam Pharmaceuticals
investing.com - April 22 at 2:13 PM
Analysts Estimate Alnylam Pharmaceuticals (ALNY) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Alnylam Pharmaceuticals (ALNY) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - April 22 at 2:13 PM
PCSK9 Inhibitors Market Size, Share, Pricing Strategy, Development Trends, Modest Analysis and Forecasts to 2026PCSK9 Inhibitors Market Size, Share, Pricing Strategy, Development Trends, Modest Analysis and Forecasts to 2026
marketwatch.com - April 22 at 8:57 AM
DateCompanyBrokerageAction
4/20/2021Zai LabSVB LeerinkBoost Price Target
4/13/2021Zai LabThe Goldman Sachs GroupBoost Price Target
4/13/2021Zai LabGuggenheimBoost Price Target
2/8/2021Zai LabJefferies Financial GroupBoost Price Target
11/16/2020Zai LabJPMorgan Chase & Co.Boost Price Target
12/30/2019Zai LabCitigroupBoost Price Target
9/4/2019Zai LabChina Renaissance SecuritiesInitiated Coverage
7/12/2019Zai LabBank of AmericaInitiated Coverage
7/5/2019Zai LabMacquarieInitiated Coverage
1/29/2019Zai LabCredit Suisse GroupInitiated Coverage
4/28/2021BioMarin PharmaceuticalWedbushReiterated Rating
4/26/2021BioMarin PharmaceuticalMorgan StanleyLower Price Target
3/8/2021BioMarin PharmaceuticalEvercore ISIUpgrade
3/8/2021BioMarin PharmaceuticalCanaccord GenuityLower Price Target
3/1/2021BioMarin PharmaceuticalRobert W. BairdReiterated Rating
9/10/2020BioMarin PharmaceuticalTruistLower Price Target
8/20/2020BioMarin PharmaceuticalOppenheimerLower Price Target
8/20/2020BioMarin PharmaceuticalWilliam BlairReiterated Rating
8/19/2020BioMarin PharmaceuticalRoyal Bank of CanadaDowngrade
8/19/2020BioMarin PharmaceuticalStifel NicolausDowngrade
5/11/2021Elanco Animal HealthG.ResearchUpgrade
5/11/2021Elanco Animal HealthGabelliUpgrade
5/11/2021Elanco Animal HealthBarclaysUpgrade
3/22/2021Elanco Animal HealthRaymond JamesReiterated Rating
12/9/2020Elanco Animal HealthArgusDowngrade
11/17/2020Elanco Animal HealthCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
7/27/2020Elanco Animal HealthCleveland ResearchDowngrade
4/20/2021Alnylam PharmaceuticalsNeedham & Company LLCReiterated Rating
2/12/2021Alnylam PharmaceuticalsHC WainwrightBoost Price Target
1/25/2021Alnylam PharmaceuticalsBMO Capital MarketsDowngrade
1/13/2021Alnylam PharmaceuticalsCowenBoost Price Target
12/17/2020Alnylam PharmaceuticalsPiper SandlerBoost Price Target
10/12/2020Alnylam PharmaceuticalsChardan CapitalReiterated Rating
9/30/2020Alnylam PharmaceuticalsBerenberg BankInitiated Coverage
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.